2. Academic Validation
  3. Eradication of Pseudomonas aeruginosa Persister Cells by Eravacycline

Eradication of Pseudomonas aeruginosa Persister Cells by Eravacycline

  • ACS Infect Dis. 2024 Dec 13;10(12):4127-4136. doi: 10.1021/acsinfecdis.4c00349.
Sweta Roy 1,  Zeynep S Cakmak 1,  Salma Mahmoud 2,  Mahsa Sadeghzadeh 2,  Guirong Wang 2 3,  Dacheng Ren 1 4 5 6
Affiliations

Affiliations

  • 1 Department of Biomedical and Chemical Engineering, Syracuse University, Syracuse, New York 13244, United States.
  • 2 Department of Surgery, SUNY Upstate Medical University, Syracuse, New York 13210, United States.
  • 3 Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, New York 13210, United States.
  • 4 BionInspired Institute, Syracuse University, Syracuse, New York 13244, United States.
  • 5 Department of Civil and Environmental Engineering, Syracuse University, Syracuse, New York 13244, United States.
  • 6 Department of Biology, Syracuse University, Syracuse, New York 13244, United States.
PMID: 39537364 DOI: 10.1021/acsinfecdis.4c00349
Abstract

Pseudomonas aeruginosa is a leading Bacterial pathogen that causes persistent infections. One major reason that Antibiotics fail to clear such infections is the presence of a dormant subpopulation called persister cells. To eradicate persister cells, it is important to change drug development from traditional strategies that focus on growth inhibition to the search for new leads that can kill dormant cells. In this study, we demonstrate that eravacycline can effectively accumulate in P. aeruginosa persister cells, leading to strong killing during wakeup, including persister cells in both planktonic cultures and biofilms of the wild-type strain and its mucoid mutant. The effects of eravacycline on persister control were further validated in vivo using a lung Infection model in mice. Collectively, these results demonstrate the possibility to control persister cells of Bacterial pathogens by targeting dormancy.

Keywords

P. aeruginosa; antibiotic; bacterial pneumonia model; biofilm; eravacycline; persister.

Figures
Products